摘要:
The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.
摘要:
The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.
摘要:
The present invention relates to heterocyclic compounds which are positive modulatorsof metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.
摘要:
The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for treating and/or preventing diseases, and to medicaments containing them.
摘要:
The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors in order to treat diseases modulated by 5-HT5 receptor activity, especially treat neurodegenerative and neuropsychiatric disorders and the signs, symptoms, and malfunctions associated therewith.
摘要翻译:胍化合物(I),它们的对映异构体,非对映体和/或互变异构体和盐是新的。 式(I)的胍化合物,其对映异构体,非对映异构体和/或互变异构体和盐是新的。 Q-N(R 2) - C(= NR 3) - N(R 1) - Z-W(I)W:取代的苯基或噻吩基; Z: - (CR 1> zR 2> z)a-(V z)b-(CR 3> zR 4> z)c-; a和c:0-4; b:0或1,a,b和c的和= 1-5; R 1> z至R 4> z:氢,卤素,羟基,1-6C烷基,2-6C烯基或炔基,1-6C亚烷基(3-7C)环烷基,3-7C环烷基,(杂)芳基, -4C亚烷基(杂)芳基或R 1> z / R 2> z和/或R 3> z / R 4> z一起完成3-7元任选取代的(未)饱和碳 - 或杂环基, 含有多达3个杂原子(O,N或S); V z:CO,CONR 5> z,NR 5> zCO,O,S,SO,SO 2,SO 2 NR 5> z,NR 5> zSO 2,CS,CSNR 5> z,NR 5> zCS, OCS,COO,OCO,O,亚乙烯基,C(= CR 6)z R 7 z),CR 6> z = CR 7> z,NR 5> zCONR 5>,OCONR 5> z或NR 5> z; R 1> -R 3>:氢或取代基; Q:二取代的5元杂芳基。 “定义(完全定义)”字段中给出了完整的定义。 活动:反义词 神经保护; 精神药物; 脑保护; 镇惊; 抗精神病药; 安神; 抗抑郁药; 抑制细胞生长; 止痛; 解酒。 没有给出这些活动的测试细节。 作用机制:5-羟色胺(5HT)5类受体非竞争性抑制剂。 (I)结合5-羟色胺(5HT)5类受体作为非竞争性抑制剂,因此(最终)细胞内钙离子浓度的增加。 化合物N-(2-甲氧基苄基)-N' - (1,3-噻唑-2-基)胍(Ia)对于低于50nM的人5-HT 5受体具有结合亲和力(抑制常数)。
摘要:
The present invention relates to tetraline and indane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetraline and indane derivatives, and the use of such tetraline and indane derivatives for therapeutic purposes. The tetraline and indane derivatives are GlyT1 inhibitors.